More than half of clinicians surveyed do not think patients know that PCPs and nurse practitioners (NPs) are fully trained to diagnose and treat mental health issues.
“When a patient comes to my office, they may not even be aware that their symptoms could indicate depression, anxiety or another mental health issue,” said
More than half of PCPs said they wait to discuss specific mental health conditions like depression and anxiety until a patient raises a concern or until the results of a screening/assessment indicate the need.
“I felt comfortable talking with Michele about my mental health issues because she created a warm and nurturing environment,” said Beth, a patient at
Treat vs Refer: The Primary Care Challenge
More than six in 10 (63%) MSPs/NPs have increased referrals to mental health specialists over the past two years, despite the shortage of available care.
“Primary care providers are now fighting two battles at once: more and more patients are experiencing mental health issues, but there are fewer specialists available to refer them to,” said
According to the GeneSight Mental Health Monitor, only 18% of responding primary care prescribers use an available tool like pharmacogenomic testing to inform their mental health medication treatment plan.
Pharmacogenomics (PGx) tests, such as the GeneSight psychotropic test, can help PCPs manage the mental health of their patients. The GeneSight test analyzes clinically important genetic variations that can impact how a patient metabolizes and responds to certain FDA-approved drugs used to treat depression, anxiety, ADHD, and other conditions of mental health. The test is intended to supplement other information considered by a clinician as part of a comprehensive medical evaluation.
Before seeing Michele, Beth saw another doctor who prescribed her medication for depression, but it didn’t help her feel better. in fact, she said “I didn’t feel any emotion.” Michele ordered the GeneSight test for Beth and used the information to change her prescription. Today, Beth says she “feels so much better” and more like herself.
The report provides clinicians with information about drugs that may need dose adjustments, be less likely to work, or have an increased risk of side effects based on a patient’s genetic information.
“Using GeneSight has greatly reduced the number of referrals I make to other specialists,” said
About the GeneSight Mental Health Monitor
The GeneSight Mental Health Monitor is a national survey of primary care physicians and nurse practitioners conducted online by
About GeneSight® Test
The GeneSight psychotropic test of
Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, SneakPeek, Health.Illuminated., RiskScore , Prolaris, UroSuite, GeneSight and EndoPredict are trademarks or registered trademarks of
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the benefits of the GeneSight psychotropic test. These “forward-looking statements” are based on management’s expectations regarding future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause the results, conditions and actual events differ materially and adversely from those anticipated. These factors include the risks described in the Company’s filings with the
2022 GlobeNewswire, Inc., source
#GeneSight #mental #health #monitor #reveals #gap #frontline #mental #health #care #MarketScreener